ReviewDiscover oncology2026
Overcoming domain-specific challenges for artificial intelligence in abdominal oncology toward clinical translation.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is advancing clinical oncology, yet its application to abdominal tumors presents distinct challenges compared to other cancer types. This review analyzes the role of machine intelligence specifically in abdominal oncology, focusing on its scope in detection, diagnosis, and treatment optimization. We find that AI systems, particularly computer-aided detection (CAD) and diagnosis (CADx), demonstrate high performance in tumor identification and characterization. Furthermore, radiomics powered by these computational tools can non-invasively predict molecular profiles, aiding personalized therapy. However, key challenges—including data heterogeneity, model generalizability, ethical concerns, and regulatory gaps—hinder robust clinical integration. This review synthesizes current applications, critically examines domain-specific limitations, and proposes a framework for translating AI advancements into improved clinical management of abdominal tumors. Future directions to bridge this translational gap include privacy-preserving federated learning, explainable AI for clinical trust, and rigorous multi-center validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.